AllllSevens
Stock-Market Research, Institutional Trading & Market Inefficiencies
Moderna looks likely to stay relatively stable above its gap-up price into next year, as big buyers return. A $6M sale of March 2027 $110 puts bets on exactly that, which seems logical. Yesterday's $30B was the second-largest dollar buy volume ever for the stock, after buy volumes had already re-emerged; January's buying, the largest since Q2 2024, came when the stock was above $100, versus about $50 now. x.com x.com
Moderna could rise further with strong call flow showing, but it is getting close to a top expected in late October or early November; take profits on the way up. x.com
Moderna could get explosive above $200 as anyone who shorted last week's valuation downgrade has to cover. The shakeout on that downgrade was a killer opportunity, and the stock is now back over $200. x.com
Moderna's approaching October 24 data release at a Madrid conference makes some pre-event profit-taking likely. After the release, the stock could be $400, $200 or $40; the outcome is unknown. x.com
Moderna looks like a logical play on plague-outbreak concerns, though this is outside areas of expertise. A Russian lab worker's sudden death has raised fears of a plague crisis, per Zero Hedge, with the Trump team monitoring the outbreak, and the stock is acting well. x.com
Moderna's oncology franchise has been repriced by the Merck-partnered INTerpath-001 melanoma vaccine trial, a watershed moment. Argus upgraded the stock to Buy with a $180 target, noting shares remain more than 70% below their old highs, and Moderna closed an upsized $2.6 billion convertible note to fund oncology growth. The stock is consolidating in a tight pennant after its biggest gap up in years; a move above $156.13 targets $161.37, then $176.66. x.com
Moderna's data catalyst is done, and it won't get an early stop in RCC. That makes it a good short here, with the story over until at least next summer. x.com
Moderna is extremely attractive because curing cancer is a big story, but more consolidation is likely first. The weekly chart shows a wide gap between price and the upper Bollinger Band, so volatility may need another week or two to ebb before the stock possibly starts moving higher. x.com
Moderna's cancer-cure mystery and optimism are the conditions that drive big stock moves. Its theme is now hot to trade, alongside related stocks. CoreWeave's 2025 AI data-center IPO rode similar uncertainty about AI revenue while AI was hot; it now faces AI-spending worries. x.com
Moderna has almost 40% downside to its average analyst price target of $119.56, which makes the sudden rush to buy it hard to explain. x.com
Pfizer looks set to rebound toward $30-$35 after about $2M of insider buying around $25. If Moderna can rally this year, so can this once-beloved pharma name. x.com
